Breast Cancer

Elacestrant, an oral selective estrogen receptor degrader, will undergo evaluation by the FDA for patients with estrogen receptor–positive/HER2-negative advanced or metastatic breast cancer.

Contextualizing the use of T-DXd in breast cancer and gastric cancers respectively, panelists highlight optimal management of adverse events in these settings.

After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.

The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.

The FDA has approved the first targeted therapy for patients with HER2-low metastatic breast cancer.

Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.

In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.

Based on data from the DESTINY-Breast04 trial, the FDA has granted a priority review designation for the supplemental biologics license application for fam-trastuzumab deruxtecan-nxki.

Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.

Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.

Patients with breast cancer who experience adjuvant hormone therapy (AHT)-related hot flashes and are treated for hot flashes at the beginning of therapy had worse outcomes than those who did not.

Facility characteristics at community-based breast imaging facilities may be linked to screening disparities across ethnic and racial groups.

The NCCN guidelines have been amended to include trastuzumab deruxtecan for use in patients with HER2-low metastatic breast cancer and sacituzumab govitecan for use in patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

At the 2022 Supportive Care in Cancer Annual Meeting, Jeffrey Crawford, MD, highlighted the potential value of biosimilars in reducing gaps in care for the treatment of febrile neutropenia.

Approximately 140 in 100,000 pregnant women receive a cancer diagnosis. Of these diagnoses, 0.1% are considered malignant tumors.

Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership.

In this episode of “The Vitals,” Sri Kota, MSN, BA, RN, OCN, reflects on nurse-specific takeaways from SABCS 2021, exciting changes in the breast cancer space, and the importance of patient education in the face of new regimens.

Patients with hormone receptor¬–positive, HER2-negative, node-positive high-risk early breast cancer who have certain characteristics may benefit from early dose adjustments with adjuvant abemaciclib.

Patients with early-stage breast cancer who have low vitamin D counts may be at risk of developing chemotherapy-induced peripheral neuropathy.

Reducing ribociclib dosing by 200 mg or 400 mg did not affect overall survival in patients with hormone receptor–positive, HER2-negative, advanced breast cancer.

Findings from DESTINY-Breast04 (NCT03734029) support the use of trastuzumab deruxtecan in patients with hormone receptor–positive, HER2-low metastatic breast cancer.

Updated safety findings from DESTINY-Breast03 showed that treatment with trastuzumab deruxtecan was safe and tolerable for patients with HER2-positive metastatic breast cancer.

Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Although 83% of Black patients with metastatic breast cancer expressed interest in clinical trials, only 40% reported having a conversation about enrollment with their health care provider, highlighting one of many potential barriers to achieving clinical trial diversity.